Molecular Templates, Inc., formerly Threshold Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. Evofosfamide is designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not in healthy tissues. Tarloxotinib is under investigation in two Phase II proof-of-concept trials: one for the treatment of patients with mutant EGFR-positive, T790M-negative advanced NSCLC progressing on an EGFR TKI, and the other for patients with recurrent or metastatic squamous cell carcinomas of the head and neck. [18F]-HX4 is an investigational Positron Emission Tomography imaging agent for hypoxia to identify.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:MTEM
- CUSIP: 88580720
- Web: www.thresholdpharm.com
- Market Cap: $140.59 million
- Outstanding Shares: 26,881,000
- 50 Day Moving Avg: $5.37
- 200 Day Moving Avg: $5.70
- 52 Week Range: $3.85 - $16.28
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.63
- P/E Growth: 0.00
- Return on Equity: -77.61%
- Return on Assets: -61.41%
- Current Ratio: 8.41%
- Quick Ratio: 8.41%
- Average Volume: 70,672 shs.
- Beta: 3.31
Frequently Asked Questions for Threshold Pharmaceuticals (NASDAQ:MTEM)
What is Threshold Pharmaceuticals' stock symbol?
Threshold Pharmaceuticals trades on the NASDAQ under the ticker symbol "MTEM."
When did Threshold Pharmaceuticals' stock split? How did Threshold Pharmaceuticals' stock split work?
Shares of Threshold Pharmaceuticals reverse split on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 1st 2017. An investor that had 100 shares of Threshold Pharmaceuticals stock prior to the reverse split would have 9 shares after the split.
How were Threshold Pharmaceuticals' earnings last quarter?
Threshold Pharmaceuticals, Inc. (NASDAQ:MTEM) posted its earnings results on Monday, July, 31st. The company reported $0.22 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.77) by $0.99. The company earned $3 million during the quarter. View Threshold Pharmaceuticals' Earnings History.
Where is Threshold Pharmaceuticals' stock going? Where will Threshold Pharmaceuticals' stock price be in 2017?
3 brokers have issued 1-year price objectives for Threshold Pharmaceuticals' stock. Their predictions range from $0.40 to $10.00. On average, they expect Threshold Pharmaceuticals' stock price to reach $5.37 in the next year. View Analyst Ratings for Threshold Pharmaceuticals.
Who are some of Threshold Pharmaceuticals' key competitors?
Some companies that are related to Threshold Pharmaceuticals include Codexis (CDXS), Idera Pharmaceuticals (IDRA), Corvus Pharmaceuticals (CRVS), Horizon Discovery Group PLC (HZD), Curis (CRIS), Advaxis (ADXS), Nabriva Therapeutics AG (NBRV), Voyager Therapeutics (VYGR), Protagonist Therapeutics (PTGX), Arbutus Biopharma Corporation (ABUS), NewLink Genetics Corporation (NLNK), Compugen (CGEN), OncoMed Pharmaceuticals (OMED), Merrimack Pharmaceuticals (MACK), Asterias Biotherapeutics (AST), Asterias Biotherapeutics (AST), Chromadex Corp (CDXC) and Novelion Therapeutics (NVLN).
Who are Threshold Pharmaceuticals' key executives?
Threshold Pharmaceuticals' management team includes the folowing people:
- Harold E. Selick Ph.D., Chairman of the Board
- Wilfred E. Jaeger M.D., Interim Chief Executive Officer, Independent Director
- Joel A. Fernandes, Vice President - Finance, Controller
- Mark Hopkins J.D. Ph.D., Vice President - Intellectual Property and Assistant General Counsel
- Kristen Quigley, Vice President - Clinical Operations
- Tillman Pearce M.D., Chief Medical Officer
- Jeffrey W. Bird M.D. Ph.D., Independent Director
- Bruce C. Cozadd, Independent Director
- David R. Hoffmann, Independent Director
- George G. C. Parker Ph.D., Independent Director
How do I buy Threshold Pharmaceuticals stock?
Shares of Threshold Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Threshold Pharmaceuticals' stock price today?
MarketBeat Community Rating for Threshold Pharmaceuticals (NASDAQ MTEM)MarketBeat's community ratings are surveys of what our community members think about Threshold Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Threshold Pharmaceuticals stock can currently be purchased for approximately $5.23.
Consensus Ratings for Threshold Pharmaceuticals (NASDAQ:MTEM) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 2 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.67)|
|Consensus Price Target: ||$5.37 (2.74% upside)|
Analysts' Ratings History for Threshold Pharmaceuticals (NASDAQ:MTEM)
(Data available from 8/18/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/3/2017||Ladenburg Thalmann Financial Services||Initiated Coverage||Buy -> Buy||$10.00||High|
|8/3/2017||Stifel Nicolaus||Reiterated Rating||Hold||$0.40||Low|
|10/3/2016||William Blair||Reiterated Rating||Outperform||N/A|
|9/30/2016||S&P Equity Research||Lower Price Target||$7.37 -> $5.72||N/A|
|12/7/2015||Piper Jaffray Companies||Downgrade||Overweight -> Neutral||N/A|
|12/7/2015||Cowen and Company||Downgrade||Outperform -> Market Perform||N/A|
|10/5/2015||Cantor Fitzgerald||Reiterated Rating||Buy||$154.00||N/A|
|9/15/2015||Royal Bank Of Canada||Reiterated Rating||Buy||N/A|
Earnings History for Threshold Pharmaceuticals (NASDAQ:MTEM)Earnings History by Quarter for Threshold Pharmaceuticals (NASDAQ MTEM)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/31/2017||Q2 2017||($0.77)||$0.22||$3.00 million||View||N/A|
|3/10/2016||Q4||($1.21)||$9.46||$4.51 million||$65.87 million||View||N/A|
|11/2/2015||Q315||($1.54)||($0.99)||$3.69 million||$3.70 million||View||N/A|
|7/30/2015||Q2||($1.54)||($1.32)||$3.70 million||$3.68 million||View||N/A|
|4/30/2015||($1.54)||($1.87)||$3.44 million||$3.68 million||View||N/A|
|3/3/2015||Q414||($1.43)||($1.32)||$4.34 million||$3.68 million||View||N/A|
|11/3/2014||Q314||($1.32)||($1.65)||$3.82 million||$3.70 million||View||N/A|
|8/1/2014||($1.43)||($1.32)||$4.00 million||$3.68 million||View||N/A|
|5/1/2014||($1.10)||($1.32)||$9.81 million||$3.68 million||View||N/A|
|3/6/2014||Q413||($1.10)||($1.43)||$3.58 million||$3.20 million||View||N/A|
|11/4/2013||Q313||($1.54)||$0.22||$3.15 million||$3.20 million||View||N/A|
|5/2/2013||Q1 2013||($0.99)||($1.76)||$2.80 million||$2.90 million||View||N/A|
|11/2/2012||Q312||($0.66)||($0.66)||$2.29 million||$1.80 million||View||N/A|
Earnings Estimates for Threshold Pharmaceuticals (NASDAQ:MTEM)
Current Year EPS Consensus Estimate: $-1.32 EPS
Next Year EPS Consensus Estimate: $-1.44 EPS
Dividend History for Threshold Pharmaceuticals (NASDAQ:MTEM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Threshold Pharmaceuticals (NASDAQ:MTEM)
Insider Ownership Percentage: 12.97%Insider Trades by Quarter for Threshold Pharmaceuticals (NASDAQ:MTEM)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/1/2017||Jeffrey W Bird||Director||Buy||510,703||$0.57||$291,100.71|| |
|2/18/2015||Wilfred E Jaeger||Director||Buy||25,000||$3.75||$93,750.00|| |
|10/13/2014||Nipun Davar||VP||Buy||3,000||$2.99||$8,970.00|| |
|10/1/2014||Hill Ventures Sutter||Major Shareholder||Sell||226,657||$3.77||$854,496.89|| |
|10/1/2014||Jeffrey W Bird||Director||Sell||238,520||$3.77||$899,220.40|| |
|6/20/2014||David L Anderson||Major Shareholder||Sell||13,988||$4.01||$56,091.88|| |
|1/16/2014||Wilfred Jaeger||Director||Sell||96,356||$4.86||$468,290.16|| |
|1/15/2014||Wilfred Jaeger||Director||Sell||424,956||$4.87||$2,069,535.72|| |
|1/10/2014||Wilfred Jaeger||Director||Sell||723,900||$4.88||$3,532,632.00|| |
|7/15/2013||Wilfred E Jaeger||Director||Sell||322,000||$5.53||$1,780,660.00|| |
|7/11/2013||Wilfred E Jaeger||Director||Sell||178,000||$5.51||$980,780.00|| |
|7/5/2013||Wilfred E Jaeger||Director||Sell||219,667||$5.53||$1,214,758.51|| |
|6/19/2013||Wilfred E Jaeger||Director||Sell||2,000||$5.50||$11,000.00|| |
|6/18/2013||Wilfred E Jaeger||Director||Sell||124,733||$5.51||$687,278.83|| |
|6/10/2013||Wilfred E Jaeger||Director||Sell||153,600||$5.48||$841,728.00|| |
|5/31/2013||David L Anderson||Major Shareholder||Sell||266,542||$5.72||$1,524,620.24|| |
|5/31/2013||Jeffrey W Bird||Director||Sell||273,181||$5.72||$1,562,595.32|| |
|5/22/2013||Tillman Pearce||Insider||Sell||20,000||$5.63||$112,600.00|| |
Headline Trends for Threshold Pharmaceuticals (NASDAQ:MTEM)
Latest Headlines for Threshold Pharmaceuticals (NASDAQ:MTEM)
Threshold Pharmaceuticals (MTEM) Chart for Friday, August, 18, 2017